Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1–Nrf2 Protein–Protein Interaction

Authors:

Abstract
The transcription factor Nrf2 regulates the expression of a large network of cytoprotective and metabolic enzymes and proteins. Compounds that directly and reversibly inhibit the interaction between Nrf2 and its main negative regulator Keap1 are potential pharmacological agents for a range of disease types including neurodegenerative conditions and cancer. We describe the development of a series of 1,4-diphenyl-1,2,3-triazole compounds that inhibit the Nrf2–Keap1 protein–protein interaction (PPI) in vitro and in live cells and up-regulate the expression of Nrf2-dependent gene products.
Funding Information
  • Biotechnology and Biological Sciences Research Council (BB/L01923X/1)
  • School of Pharmacy, University College London
  • Cancer Research UK (C20953/A10270, C9344/A10268)
  • Medical Research Council

This publication has 46 references indexed in Scilit: